Results 71 to 80 of about 2,175,372 (155)

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

Andrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis, Lisa Schneider, Felix Bremmer, Daniel Nettersheim   +3 more
wiley   +1 more source

ALBI‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab

Alimentary Pharmacology &Therapeutics, EarlyView.
ALBI‐6, a novel score combining albumin–bilirubin grade and interleukin‐6, showed improved prognostic discrimination compared with established scores in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab, supporting its potential use for risk stratification in this setting.
Paula Bark, Lucas Wiesmann, Simon Johannes Gairing, Kateryna Shmanko, Lukas Müller, Maximilian Moos, Fabian Stöhr, Dirk Graafen, Tilman Emrich, Felix Hahn, Daniel Pinto dos Santos, Bernhard Scheiner, Victoria Berit Berger, Matthias Pinter, Valentina Zarka, Florian P. Reiter, Andreas Geier, Najib Ben Khaled, Alexander Philipp, Christoph Springfeld, Aurelie Tomczak, Michael T. Dill, Constantin Scholz, Jens Mittler, Hauke Lang, Beate Katharina Straub, Roman Kloeckner, Tobias Bäuerle, Christian Markus Lange, Arndt Weinmann, Peter Robert Galle, Friedrich Foerster   +31 more
wiley   +1 more source

AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis

Background Lenvatinib is utilized as a first‐line therapy for hepatocellular carcinoma (HCC); however, the emergence of resistance significantly impairs its clinical efficacy.
Qingbin Wang, Hongkai Zhuang, Changzhen Shang, Jiahao Jiang, Wentao Wang, Bingkun Wang, Lei Yang, Chenwei Tang, Zhiqin Xie, Xiaowu Ma, Yajin Chen   +10 more
core   +1 more source

Supranational surveillance of antimicrobial resistance: The legacy of the last decade and proposals for the future

, 2010
Antimicrobial resistance among clinically important bacteria is widely acknowledged as a major global public health threat. A decade ago, several supranational surveillance initiatives were introduced. Few of them are still ongoing, and only one features
CORNAGLIA, Giuseppe, Giske CG, European Study Group on Antimicrobial Resistance Surveillance   +2 more
core   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance

, 2019
Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) that shows improved median progression-free survival (PFS) in patients with thyroid carcinomas.
Misako Nagasaka, Mahmoud Chaker, James Ge, Mark Szlaczky, Gabriel Mpilla, Irfana Muqbil, Erkan Baloglu, Yosef Landesman, Ramzi M. Mohammad, Asfar S. Azmi, Husain Yar Khan, Amro Aboukameel, Ammar Sukari   +12 more
core   +1 more source

CDK4 inhibition by luteolin enhances lenvatinib sensitivity in HCC via Wnt/β-catenin modulation

Cancer Cell International
Background Hepatocellular carcinoma (HCC) frequently develops resistance to lenvatinib. We investigated CDK4’s role in this resistance and the potential of Danshen/luteolin to overcome it.
Baohong Yuan, Ruotian Wang, Ruhong Li, Songlin Yang, Dong Zhan, Jing Tan   +5 more
doaj   +1 more source

The nitty‐gritty of vascular permeability in cancer: targeting blood endothelium to control metastases

British Journal of Pharmacology, EarlyView.
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher, Mérone Da Costa Oliveira, Adrien Levesque, Alexandre Rutault, Patrick Savoyaud, Nicolas Bréchot, Stéphane Germain   +6 more
wiley   +1 more source

Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment

, 2019
Monica Capozzi,1 Chiara De Divitiis,2 Alessandro Ottaiano,3 Claudia von Arx,4 Stefania Scala,5 Fabiana Tatangelo,6 Paolo Delrio,1 Salvatore Tafuto11Department of Abdominal Oncology, Istituto Nazionale Tumori, IRCCS - Fondazione “G.
von Arx C, Ottaiano A, Delrio P, Capozzi M, Scala S, De Divitiis C, Tatangelo F, Tafuto S   +7 more
core  

Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050 [PDF]

Background: Antimicrobial resistance (AMR) poses an important global health challenge in the 21st century. A previous study has quantified the global and regional burden of AMR for 2019, followed with additional publications that provided more detailed ...
GBD, 2021 Antimicrobial Resistance Collaborators, GBD 2021 Antimicrobial Resistance Collaborators   +1 more
core   +1 more source